期刊文献+

体外膜肺氧合在心肺辅助循环中的应用 被引量:3

Application of ECMO in cardiopulmonary failure support
下载PDF
导出
摘要 目的 总结7例体外膜肺氧合(ECMO)在心肺辅助循环中的临床应用.方法 自2007年12月至2010年10月,对7例重症心肺功能衰竭患者进行ECMO支持治疗,所有患者均采用静脉-动脉插管行ECMO支持治疗,期间维持血流动力学和呼吸指标稳定.结果 ECMO支持时间20~48 h,平均32 h,患者建立ECMO后血流动力学及气体交换均有明显好转.其中5例患者顺利脱机,不能脱机的2例中1例在血管活性药物用量较大,ECMO流量较大的情况下仅能维持较低血压,而后心跳停止不能恢复.1例因患者肺受损严重,ECMO治疗效果不佳,肾功能衰竭,最后放弃治疗.结论 ECMO是救治心功能衰竭、呼吸功能衰竭的重要心肺辅助循环的有效手段.正确掌握其适应证、选择转流方式、良好的管理才能提高ECMO的成功率. Objective observe the application of ECMO(extracorporeal membrane oxygenation) in cardiopulmonary failure support and summarize clinical experience. Methods gave ECMO treatment to 7 patients suffering from severe cardiopulmonary failure from December 2007 to October 2010. All the 7 patients received intravenous-arterial cannula ECMO support treatment and maintained stable hemodynamic and respiratory indexes. Results ECMO support time:20-48h,32h on average. With ECMO support, hemodynamics and respiration were significantly improved. 5 patients needed no longer to receive equipment treatment. One of the remained two patients used great amount of vasoactive drugs so that low blood pressure could be maintained with large ECMO flow. After that,cardiac arrest occurred and can not be restored. Poor effect was achieved for 1 patient due to severe lung damage. In addition,the patient also suffered from renal failure. Finally,the treatment was abandoned. Conclusion ECMO is an effective means for heart failure and respiratory failure treatment for cardiopulmonary circulatory support. With proper understanding of its indication and selecting the correct bypass way,ECMO success rate can then be improved.
出处 《重庆医学》 CAS CSCD 北大核心 2011年第12期1172-1173,1176,共3页 Chongqing medicine
关键词 体外膜氧合作用 体外循环 心肺功能衰竭 extracorporeal membrane oxygenation~ extracorporeal circulation cardiopulmonary failure
  • 相关文献

参考文献14

  • 1Goldman AP,Cassidy J,Deleval M,et al.The waiting game:bridging to paediatric heart transplantation[J].Lancet,2003,362(9):967-970.
  • 2Krisa VM.ECMO:Extracorporeal cardiopulmonary support in critcal care[M].3 Edi.Michigan:Extracorporeal Life Support Orgnization,2005:467-473.
  • 3Smerdia NG,Blackstone EH.Postcardiotomy mechanical support risk-factors and outcomes[J].Ann Tborac Surg,2001,71(1):60-62.
  • 4Jaggem JJ,Forbess M,Shall AS,et al.Excorporeal membrane oxygenator for infant postcardiotanycm support significane of shunt management[J].Ann Thorac,2000,69(12):1476-1478.
  • 5Smith C,Bellcmo R,Raman JS,et al.An extracorporeal membrane oxygenation-based approach to cardiogenic shock in an older population[J].Ann Thorac Surg,2001,71:1421-1427.
  • 6龙村.ECMO手册[M].北京:人民卫生出版社,2007:5.
  • 7Kopp R,Denbinski R,Kuhlen R.Role of extracorporeal lung assist in the treatment of acute respiratory failure[J].Minerva Anestesiol,2006,72(5):587-595.
  • 8DiRosso GB,Martin GR.Excorporeal membrane oxygenation for cardiac disease no longer a mistaken diagnosis[J].Sem in Thorac Cardiovasc Surg,2005,14(1):34-40.
  • 9Magovern GJ,Magovern JA,Benckart DH,et al.Extra-corporeal menmbrane oxygenation:preliminary results in patients with posrorperative cardiogenic shock[J].Ann Thorac Surg,1994,57(6):1462-1464.
  • 10Muehrcke DD,MacCarthy PM,Stewart RW,et al.Extra-corporeal membrane oxygenation for postcardiotomy cardiogenic shock[J].Ann Thorac Surg,1996,61(5):684-691.

二级参考文献7

  • 1[1]Woodman RC.Bleeding complications associated with cardiopulmonary bypass[J].Blood,1990,76:1680-1697.
  • 2[2]Taylor K.The systemic inflammatory response syndrome after cardiac operation[J].Ann Thorac Surg,1996,61:1607-1608.
  • 3[3]Ovrum E,Mollnes TE,Fosse E,et al.High and low heparin dose with heparin-coated cardiopulmonary bypass:activation of complement and granulocyte[J].Ann Thorac Surg,1995,60:1755-1761.
  • 4[4]Sinic V,Kalaycioglu S,Gunaydin S,et al.Evaluation of heparin-coated circuits with full heparin dose strategy[J].Ann Thorac Cardiovasc Surg,1999,5(3):156-163.
  • 5[5]Jansen PGM,Tevelthuis H,Huybregts R AIM,et al.Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits[J].J Thorac Cardiovasc Surg,1995,110:829-834.
  • 6[6]Khuri SF,Valeri CR,Loscalzo J,et al.Heparin Causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass[J].Ann Thorac Surg,1995,60:1008-1014.
  • 7[7]Sellevold OF,Berg TM,Rein KA,et al.Heparin-coated circuits during Cardiopulmonary bypass.A clinical study using closed circuit,centrifugal pump and reduced heparinization[J].Acta Anaesthesiol Scand,1994,38:372-379.

共引文献31

同被引文献34

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部